AlgoTherapeutix Stock

AlgoTherapeutix is the operator of a biotechnology company designed to develop topical treatments for complex pain.

Sign up today and learn more about AlgoTherapeutix Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About AlgoTherapeutix Stock

AlgoTx creates solutions to help patients suffering from difficult-to-treat conditions. The organization accomplishes this by emphasizing conditions with no proven or licensed therapy and adapting treatment to the very particular needs of the people afflicted. ATX01's admission into Phase 2 in Chemotherapy-Induced Peripheral Neuropathy has been approved by the FDA. In the meanwhile, AlgoTx is investigating its potential in erythromelalgia, a rare and painful condition.

Funding History

November 2019$2.6M
November 2020$12.0M
March 2023$20.0M
March 2023$1.0M



Olivier Bohuon

Co-Founder, Chief Executive Officer & President

Stéphane Thiroloix

Board Member

Stéphane Thiroloix

Chief Scientific Officer

Philippe Picaut

Chief Medical Officer

Jens Ellrich


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: